We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Vistagen Therapeutics Inc (VTGN) USD0.001

Sell:$2.50 Buy:$2.60 Change: $0.25 (11.11%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$2.50
Buy:$2.60
Change: $0.25 (11.11%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$2.50
Buy:$2.60
Change: $0.25 (11.11%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Vistagen Therapeutics, Inc. is a neuroscience-focused biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for psychiatric and neurological disorders based on its understanding of nose-to-brain neurocircuitry. Its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies called pherines. Its diversified pipeline of pherine product candidates rapidly activate chemosensory neurons in the nasal cavity to impact fundamental neurocircuitry in the olfactory system and the brain. Its pipeline also includes an oral prodrug with potential to modulate N-methyl-D-aspartate receptor (NMDA) receptor activity. Its neuroscience pipeline includes five clinical-stage investigational agent, namely Fasedienol (PH94B), Itruvone (PH10), AV-101, PH15, PH80, and PH284.

Contact details

Address:
343 ALLERTON AVENUE
SOUTH SAN FRANCISCO
94080
United States
Telephone:
+1 (650) 5773600
Website:
https://www.vistagen.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VTGN
ISIN:
US92840H4002
Market cap:
$64.60 million
Shares in issue:
27.84 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Shawn Singh
    Chief Executive Officer, Director
  • Cynthia Anderson
    Chief Financial Officer
  • Joshua Prince
    Chief Operating Officer
  • Mark Mcpartland
    Senior Vice President - Investor Relations
  • Reid Adler
    Chief Corporate Development Officer, General Counsel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.